Acromegaly 
Welcome,         Profile    Billing    Logout  

19 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Acromegaly
NCT01794793 / 2013-000267-84: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Completed
4
337
Europe, Canada, Japan, US, RoW
Pasireotide, SOM230; Signifor, Cabergoline, dostinex, Pasireotide LAR
RECORDATI GROUP
Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS
07/23
07/23
2014-004386-24: Effect of pegvisomant , GH receptor competitor, using glucose in patients with acromegaly Effetto del pegvisomant, un competitore del recettore dell'ormone GH, sull'utilizzo del glucosio in pazienti con acromegalia

Ongoing
3
16
Europe
somavert, Powder and solvent for solution for injection, SOMAVERT - 10 MG POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 30 FLACONCINI + 30 FLACONCINI 8 ML SOLVENTE USO SOTTOCUTANEO
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II, Pfizer srl
acromegaly acromegalia, Growth Hormone (GH) excess disease malattia dovuta all' eccesso di ormone della crescita (GH), Diseases [C] - Hormonal diseases [C19]
 
 
2015-001292-51: Follow-Up Study in Patients that Participated in the Chiasma Study CH-ACM-01

Ongoing
3
21
Europe
Octreolin,
Chiasma, Inc., Chiasma, Inc
Acromegaly
 
 
OPTIMAL, NCT03252353 / 2017-000737-31: Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

Active, not recruiting
3
56
Europe, Canada, US, RoW
octreotide capsules, MYCAPSSA, Matching placebo, Placebo
Chiasma, Inc.
Acromegaly
06/19
05/22
NCT04076462 / 2019-001191-11: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Completed
3
72
Europe, US, RoW
CAM2029 (octreotide subcutaneous depot), CAM2029, Matching placebo, placebo
Camurus AB
Acromegaly
05/23
05/23
PATHFNDR 1, NCT04837040 / 2020-005431-70: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

Active, not recruiting
3
58
Europe, US, RoW
Paltusotine, CRN00808, Placebo
Crinetics Pharmaceuticals Inc.
Acromegaly
07/23
06/27
PATHFNDR-2, NCT05192382 / 2021-001703-32: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

Active, not recruiting
3
111
Europe, US, RoW
Paltusotine, CRN00808, Placebo
Crinetics Pharmaceuticals Inc.
Acromegaly
01/24
01/28
NCT04125836 / 2019-002190-66: A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Active, not recruiting
3
135
Europe, US, RoW
CAM2029 (octreotide subcutaneous depot), CAM2029
Camurus AB
Acromegaly
06/25
06/25
NCT04522180 / 2020-000675-20: A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly

Completed
2
34
Europe, US, RoW
GHR-LRX, ISIS 766720
Ionis Pharmaceuticals, Inc.
Acromegaly
07/22
05/23
NCT04261712 / 2019-002193-31: A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

Active, not recruiting
2
43
Europe, US, RoW
Paltusotine, CRN00808
Crinetics Pharmaceuticals Inc.
Acromegaly
03/28
03/28
NCT05761431: A Single-dose Study of Octreotide Injection in Healthy Adult Subjects

Completed
1
56
RoW
SYHX2008 injection, Octreotide Acetate Microspheres for Injection injection, Sandostatin ® injection, Placebo to SYHX2008 injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Acromegaly
06/23
06/23
NCT06372652: A Phase 1 Study of TE-8214 Solution in Healthy Volunteers

Active, not recruiting
1
32
RoW
TE-8214 - SAD, Placebo
Immunwork, Inc.
Acromegaly
10/24
01/25
OXTEND-01, NCT05364944: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Terminated
1
20
Europe, RoW
Debio 4126, Sandostatin LAR, Octreotide acetate, Somatuline ATG, Lanreotide acetate
Debiopharm International SA
Acromegaly, GEP-NET
10/24
12/24
NCT03043586: Treatment Patterns and Treatment Outcomes for Acromegaly

Active, not recruiting
N/A
520
US
Columbia University, Ipsen
Acromegaly
07/25
07/25
NCT05184231: Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China

Withdrawn
N/A
216
NA
Ipsen
Acromegaly
10/23
10/23
BackSOM, NCT06253897: A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly

Completed
N/A
20
US
Ipsen
Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly
12/24
12/24
NCT05431803: Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

Completed
N/A
129
RoW
Ipsen
Acromegaly
12/24
12/24
NCT05752825: Acromegaly: Balance, Falls and Fracture Risk

Completed
N/A
34
Europe
HR-pQCT, High Resolution peripheral Quantitative Computed Tomography, DXA scan, Dual X-ray Absorptiometry, Bone microindentation, OsteoProbe, Hand grip and leg extension strength, Timed up-and-go test, Stabilometry, Balance board, Nerve conduction test, Visual acuity test
Christian Alexander H Rosendal, Ipsen, Pfizer
Acromegaly
05/24
05/24
NCT05131100: Korean Regulatory Post Marketing Surveillance for Somavert

Recruiting
N/A
100
RoW
Somavert
Pfizer
Acromegaly
09/26
09/26

Download Options